CAMAGÜEY.- From this Monday the second phase of the Ismaelillo study began in Camagüey. After the approval of the State Center for the Control of Medicines and Medical Devices (Cecmed) to increase the sample, after successfully concluding the initial stage, it is now vaccinated in the nine health areas of the territory and the Abdala vaccine will reach another 300 childs.
Safety, the main parameter to be measured in the first phase of this type of trial, was tested in the previous two weeks, without significant adverse reactions and the immunogenicity developed by the vaccine in children is now being studied. During this initial period, as in the current extension, the doses are applied to adolescents between 12 and 18 years of age.
It is expected that before the end of the current week, immunization will also begin in small groups of 3 to 12 years, all healthy and with follow-up exams to know the evolution of their body's antibodies against the vaccine. Gradually, it will be extended to complete the figure of 592.
The Ismaelillo trial will test the immunogenicity generated by Abdala between 3 and 18 years of age, which will allow its use to expand to the entire pediatric population of Cuba.
- Translated by Linet Acuña Quilez